Recent advances and limitations in the application of kahalalides for the control of cancer
Document Type
Article
Publication Date
4-1-2022
Abstract
Since the discovery of the kahalalide family of marine depsipeptides in 1993, considerable work has been done to develop these compounds as new and biologically distinct anti-cancer agents. Clinical trials and laboratory research have yielded a wealth of data that indicates tolerance of kahalalides in healthy cells and selective activity against diseased cells. Currently, two molecules have attracted the greates level of attention, kahalalide F (KF) and isokahalalide F (isoKF, Irvalec, PM 02734, elisidepsin). Both compounds were originally isolated from the sarcoglossan mollusk Elysia rufescens but due to distinct structural characteristics it has been hypothesized and recently shown that the ultimate origin of the molecules is microbial. The search for their true source has been a subject of considerable research in the anticipation of finding new analogs and a culturable expression system that can produce sufficient material through fermentation to be industrially relevant.
Keywords
16SrRNA, Akt, Anti-psoriatic, Bryopsis, Cancer, Cytochrome c oxidase I, Cytotoxicity, Depsipeptide, Elisidepsin, ErbB, GLPORYx, Her2, Her3, Isokahalalide, Kahalalide A, Kahalalide G, Kahalalide, MAPK, Mollusk, Oncosis
Divisions
Science
Funders
United States Department of Health & Human Services National Institutes of Health (NIH) - USA[R01 DK124553],United States Department of Health & Human Services National Institutes of Health (NIH) - USA[R21 CA246233]
Publication Title
Biomedicine & Pharmacotherapy
Volume
148
Publisher
Elsevier
Publisher Location
65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE